Medical Device News Magazine

Genexa Launches Clean Line of Kids’ Medicine in Whole Foods Market

Parents Can Now Purchase Genexa’s Effective Over-the-Counter Medicines at Whole Foods Market

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

As the impending cold and flu season draws near, Genexa proudly announces the debut of its highly acclaimed clean, and effective, line of over-the-counter (OTC) children’s medicines at Whole Foods Market stores. Genexa Kids’ Pain & Fever (acetaminophen), Kids’ Allergy (diphenhydramine), and Kids’ Tummy Relief (calcium carbonate) medicines will be available at Whole Foods Markets Stores nationwide and provide parents with OTC options that comply with Genexa’s stringent ingredient standards that ban many ingredients commonly found in other OTCs. In addition, most products are certified vegan and all are certified gluten-free.

“As confirmation of all that Genexa has accomplished, we are proud to be able to share that we have been awarded a patent for our Kids’ and Infants’ Pain & Fever liquid acetaminophen formulation. And, we are also so proud to have our OTC products on shelf at Whole Foods,” said Genexa CEO David Johnson.

Genexa Kids’ Pain & Fever is an oral suspension for kids ages 2-11. The patented formula is available in two flavors—blueberry and cherry. It’s sweetened with agave syrup, resulting in no medicine after-taste. For kids who don’t like taking liquid medicine, Kids’ Pain & Fever Chewable is another option. The chewable tablets come in a tasty grape flavor.

Arriving just in time at Whole Foods Market for the holidays, Kids’ Tummy Relief for ages 2+ provides the same 400mg of calcium carbonate per tablet as Pepto Bismol® Kids Chewable Tablets Bubblegum. The chewable tablets offer soothing relief from heartburn, acid indigestion, and upset stomach and come in delicious berry and vanilla flavors that meet Genexa’s stringent ingredient standards.

Genexa’s best-selling Kids’ Allergy for ages 6+ contains the same 12.5mg of diphenhydramine HCl per 5mL as Children’s BENADRYL® Allergy Liquid Cherry. This product is flavored with soothing agave syrup and provides temporary relief from common allergy symptoms.

In addition to the children’s line, Whole Foods Market also carries Genexa’s adult pain relievers Acetaminophen Extra Strength and Acetaminophen PM. Acetaminophen Extra Strength is the first clean adult pain reliever with the same 500mg of acetaminophen per caplet as TYLENOL® Extra Strength Caplets, but without ingredients like titanium dioxide, although deemed safe by the FDA, that don’t meet Genexa’s stringent ingredient standards. Unlike most adult acetaminophen options currently available, Acetaminophen Extra Strength is certified vegan.

As a Certified B-Corporation, Genexa is committed to using business as a force for good, meeting rigorous standards of social and environmental performance, accountability, and transparency. For more information, visit Genexa.com.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”